What is Seretide®?

Seretide treats asthma and COPD (Chronic Obstructive Pulmonary Disease). Seretide, is available in two devices: an Inhaler (puffer) and an Accuhaler. Seretide contains the active ingredients fluticasone propionate and salmeterol xinafoate. Your doctor will have prescribed the device and strength right for you. Seretide is fully funded.

To find out more about Seretide please visit

Consumer Medicine Information on Seretide Accuhaler.
Consumer Medicine Information on Seretide Inhaler.

Seretide® (fluticasone propionate/salmeterol xinafoate; available as a 50/25, 125/25 or 250/25 micrograms per actuation inhaler, or as a 100/50 or 250/50 micrograms per actuation Accuhaler®) is a Prescription Medicine for the treatment of reversible obstructive airway disease (ROAD) including asthma, and for the treatment of chronic obstructive pulmonary disease (COPD). Seretide is a fully funded medicine. Seretide 250/25 microgram inhaler is a private purchase medicine that you will need to pay for. Use strictly as directed. Seretide is not for relief of acute symptoms. Always carry your reliever inhaler. Do not discontinue Seretide abruptly. Tell your doctor: If you are taking any other medicines or herbal remedies, you have pulmonary tuberculosis (TB), a thyroid problem or a heart problem, or you are having treatment for high blood pressure. Side Effects may include: Headache, 'shaky' feeling, fast heart rate, irritation in the nose and throat. If symptoms continue or you have side effects, see your doctor, pharmacist or health professional. For more information, see Seretide Consumer Medicine Information at Normal doctor's office visit fees apply. Ask your doctor if Seretide is right for you.

Seretide and Accuhaler are registered trade marks of the GlaxoSmithKline group of companies. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NA 6923-14FE

^ Back to top
New Zealand

Our products